Profitelligence Profitelligence · Filing Ledger Open AMGN research →

Form 8-K · Current Report · Filed 2024-08-06

Amgen Announces Second Quarter 2024 Financial Results

Amgen Inc. reported a 20% increase in total revenues to $8.4 billion for the second quarter of 2024, compared to $6.99 billion in the second quarter of 2023. Product sales grew by 20%, driven by volume growth, partially offset by lower net selling prices. GAAP earnings per share (EPS) decreased by 46% from $2.57 to $1.38, whereas non-GAAP EPS decreased by 1% from $5.00 to $4.97. Free cash flow for the second quarter was $2.2 billion, down from $3.8 billion in the same period of 2023.

Filer
Amgen Inc. AMGN · NASDAQ
Filed
Accession
0000318154-24-000033
CIK
0000318154
Signal
Low impactHealthcare

Items reported

Item 2.02

Results of Operations and Financial Condition

General Statement
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$325.22

Next session

-3.9%

Since filing

+18.4%

Latest close

$385.16

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from AMGN reporting the same item, with the next session's move:

Exhibits (1)

About Amgen Inc.

Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another AMGN filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts